Status:
COMPLETED
Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
Lead Sponsor:
Gulhane School of Medicine
Conditions:
We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium based phos...
Detailed Description
CKD stage 4 patients older than 18 years of age and willing to participate to the study were screened. Those who had serum phosphorus \> 5.5 mg/dl were evaluated for the study. Patients with diabetes ...
Eligibility Criteria
Inclusion
- CKD stage 4 patients
- Older than 18 years of age
- Non-diabetic
- Serum phosphorus \> 5.5 mg/dl
Exclusion
- Diabetes mellitus
- History of coronary artery disease
- Smokers
- Taking statins or renin-angiotensin blockers
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01135615
Start Date
January 1 2008
End Date
May 1 2010
Last Update
July 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gulhane School of Medicine
Ankara, Turkey (Türkiye), 06018